What is HC Wainwright’s Forecast for LPTX Q1 Earnings?

Leap Therapeutics, Inc. (NASDAQ:LPTX) – Stock analysts at HC Wainwright issued their Q1 2026 EPS estimates for shares of Leap Therapeutics in a research report issued to clients and investors on Wednesday, May 14th. HC Wainwright analyst S. Ramakanth expects that the company will post earnings per share of ($0.12) for the quarter. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Leap Therapeutics’ current full-year earnings is ($1.84) per share. HC Wainwright also issued estimates for Leap Therapeutics’ Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.13) EPS and Q4 2026 earnings at ($0.15) EPS.

Leap Therapeutics (NASDAQ:LPTX) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.01.

Several other brokerages also recently commented on LPTX. Baird R W downgraded shares of Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 29th. Robert W. Baird downgraded shares of Leap Therapeutics from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $9.00 to $1.25 in a report on Wednesday, January 29th.

Leap Therapeutics Price Performance

Shares of NASDAQ:LPTX opened at $0.41 on Thursday. The firm has a fifty day moving average price of $0.37 and a two-hundred day moving average price of $1.59. Leap Therapeutics has a one year low of $0.22 and a one year high of $4.79. The company has a market cap of $17.07 million, a price-to-earnings ratio of -0.21 and a beta of -0.17.

Institutional Trading of Leap Therapeutics

Hedge funds have recently made changes to their positions in the stock. Prosperity Wealth Management Inc. bought a new stake in shares of Leap Therapeutics during the 4th quarter worth $63,000. Jane Street Group LLC bought a new stake in Leap Therapeutics in the fourth quarter worth $107,000. Dauntless Investment Group LLC purchased a new stake in Leap Therapeutics during the fourth quarter valued at about $144,000. NewEdge Advisors LLC grew its stake in shares of Leap Therapeutics by 1,668,066.7% during the fourth quarter. NewEdge Advisors LLC now owns 50,045 shares of the company’s stock valued at $144,000 after buying an additional 50,042 shares during the last quarter. Finally, HB Wealth Management LLC grew its stake in shares of Leap Therapeutics by 103.2% during the fourth quarter. HB Wealth Management LLC now owns 51,500 shares of the company’s stock valued at $150,000 after buying an additional 26,150 shares during the last quarter. 30.46% of the stock is owned by institutional investors.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.